| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced NSCLC: new cytostatic agents
|
Kosmidis, Paris A
|
|
2003
|
41 |
S1 |
p. 123-132
10 p.
|
artikel
|
| 2 |
Angiogenesis inhibitors under study for the treatment of lung cancer
|
Shepherd, Frances A
|
|
2003
|
41 |
S1 |
p. 63-72
10 p.
|
artikel
|
| 3 |
An overview of farnesyltransferase inhibitors and their role in lung cancer therapy
|
Adjei, Alex A
|
|
2003
|
41 |
S1 |
p. 55-62
8 p.
|
artikel
|
| 4 |
Antisense oligonucleotides for cancer therapy—an overview
|
Stahel, Rolf A.
|
|
2003
|
41 |
S1 |
p. 81-88
8 p.
|
artikel
|
| 5 |
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors
|
Bonomi, Philip
|
|
2003
|
41 |
S1 |
p. 43-48
6 p.
|
artikel
|
| 6 |
Contents
|
|
|
2003
|
41 |
S1 |
p. v-
1 p.
|
artikel
|
| 7 |
Contents continued
|
|
|
2003
|
41 |
S1 |
p. vi-
1 p.
|
artikel
|
| 8 |
Cyclin D1 as a target for chemoprevention
|
Petty, W.Jeffrey
|
|
2003
|
41 |
S1 |
p. 155-161
7 p.
|
artikel
|
| 9 |
Editorial Board
|
|
|
2003
|
41 |
S1 |
p. IFC-
1 p.
|
artikel
|
| 10 |
EGF receptor as a therapeutic target
|
Levitzki, Alexander
|
|
2003
|
41 |
S1 |
p. 9-14
6 p.
|
artikel
|
| 11 |
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies
|
Hirsch, Fred R.
|
|
2003
|
41 |
S1 |
p. 29-42
14 p.
|
artikel
|
| 12 |
Gefitinib (Iressa) trials in non-small cell lung cancer
|
Johnson, David H.
|
|
2003
|
41 |
S1 |
p. 23-28
6 p.
|
artikel
|
| 13 |
Genetic testing for chemotherapy in non-small cell lung cancer
|
Rosell, Rafael
|
|
2003
|
41 |
S1 |
p. 97-102
6 p.
|
artikel
|
| 14 |
Imatinib in small cell lung cancer
|
Soria, Jean-Charles
|
|
2003
|
41 |
S1 |
p. 49-53
5 p.
|
artikel
|
| 15 |
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
|
Mack, Philip C.
|
|
2003
|
41 |
S1 |
p. 89-96
8 p.
|
artikel
|
| 16 |
Introduction
|
Hirsch, Fred R
|
|
2003
|
41 |
S1 |
p. 1-
1 p.
|
artikel
|
| 17 |
Lung cancer chemoprevention: moving from concept to a reality
|
Mulshine, James L.
|
|
2003
|
41 |
S1 |
p. 163-174
12 p.
|
artikel
|
| 18 |
Lung cancer vaccines and gene therapy
|
Hege, Kristen M.
|
|
2003
|
41 |
S1 |
p. 103-113
11 p.
|
artikel
|
| 19 |
Molecular staging and pharmacogenomics
|
Franklin, Wilbur A.
|
|
2003
|
41 |
S1 |
p. 147-154
8 p.
|
artikel
|
| 20 |
Ongoing and future trials of biologic therapies in lung cancer
|
Bunn Jr., Paul A.
|
|
2003
|
41 |
S1 |
p. 175-186
12 p.
|
artikel
|
| 21 |
Targeted molecular mechanisms of epoetin alfa
|
Langer, Corey J.
|
|
2003
|
41 |
S1 |
p. 133-145
13 p.
|
artikel
|
| 22 |
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting
|
Vokes, Everett E.
|
|
2003
|
41 |
S1 |
p. 115-121
7 p.
|
artikel
|
| 23 |
Targeted therapy in non-small cell lung cancer: myth or reality
|
Johnson, David H.
|
|
2003
|
41 |
S1 |
p. 3-8
6 p.
|
artikel
|
| 24 |
The importance of the eicosanoid pathway in lung cancer
|
Laskin, Janessa J.
|
|
2003
|
41 |
S1 |
p. 73-79
7 p.
|
artikel
|
| 25 |
Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know
|
Raben, David
|
|
2003
|
41 |
S1 |
p. 15-22
8 p.
|
artikel
|
Tijdschrift beschrijving